Recombinant collagen in skincare

Collagen is the most abundant protein in mammals and the structural backbone of dermis, tendon and bone. Producing it recombinantly removes the animal source and with it the prion and viral-clearance burden and the antigenic telopeptides of extracted collagen. What it does not remove is the chemistry that makes the molecule work.

The helix is a geometric argument

Collagen’s repeating unit is Gly-X-Y, where X is frequently proline and Y frequently 4-hydroxyproline. Three chains wind into a right-handed superhelix of left-handed polyproline-II strands. Glycine at every third position is not a preference but a requirement: it is the only residue small enough to sit at the crowded helix axis, and substituting anything larger there distorts or breaks the helix — the molecular basis of osteogenesis imperfecta mutations.

Stability comes from hydroxyproline. Prolyl-4-hydroxylase adds a hydroxyl at the 4-position of proline in the Y position, using Fe(II), 2-oxoglutarate and molecular oxygen, with ascorbate required to keep the iron reduced. The added hydroxyl works mainly through a stereoelectronic effect: it locks the pyrrolidine ring into the pucker that favours the backbone angles the helix needs. Without it, the triple helix has a melting temperature well below body temperature and simply unfolds.

Why the host matters more than the gene

This is why expressing a collagen gene alone gives an unfolded chain. Bacteria and yeast have no prolyl-4-hydroxylase acting on collagen, so functional production requires co-expressing both subunits of the enzyme — the catalytic α subunit and the β subunit, which is protein disulfide isomerase. Yeast systems such as Pichia pastoris are used this way; plant and mammalian cell systems have also been engineered. The alternative, widely taken in cosmetics, is to sidestep the problem: express short collagen-like fragments or single triple-helical domains, which are easier to make and to keep soluble but which are not full-length collagen and generally do not self-assemble into fibrils, because fibril assembly depends on the telopeptides and on the staggered charge pattern of the intact molecule.

Topically, size decides everything

Intact type I collagen is roughly 300 kDa and about 300 nm long. The stratum corneum’s lipid lamellae admit small, moderately lipophilic molecules — the working rule of thumb is a few hundred daltons — so an intact collagen molecule cannot cross intact skin, and neither can most of the fragments sold as recombinant collagen. What a topical collagen actually does is form a hydrophilic film that binds water and reduces transepidermal water loss, which measurably improves surface hydration and the appearance of fine lines while it is present. That is a real effect, and it is not the same claim as replenishing dermal collagen.

Injected or implanted, the picture changes: the material is placed where the structure is needed, and the questions become fibril assembly, resorption rate, and the immune response to a protein that is human in sequence but bacterial or fungal in post-translational context. Those products are regulated as medical devices in the EU under Regulation 2017/745, while topical formulations fall under the Cosmetic Products Regulation 1223/2009 — a distinction that follows the route of administration rather than the molecule.